F. Nekka, J. Li and F. Fenneteau What Additional Information Can we Retrieve When Compliance is Accounted For? An explicit Compliance-Pharmacokinetic Formalism
|
Jeroen Schaap Interspecies Population Modeling Of Pharmacokinetic Data Available At The End Of Drug Discovery
|
Sau Yan Amy Cheung (1), James W. T. Yates (2), Oneeb Majid (3), Leon Aarons (4) Identifiability Analysis and Parameter List Reduction of a Nonlinear Cardiovascular PKPD Model
|
Brendel K1,2, Comets E1, Laffont C.M2, Mentré F1,3. Normalized Prediction Distribution Error for the Evaluation of Nonlinear Mixed-Models
|
JF Standing (1,2), RF Howard (1,3), A Johnston (4), I Savage (2), ICK Wong (1,2,3) Developmental Pharmacokinetics of Diclofenac for Acute Pain
|
Radojka M. Savic and Mats O. Karlsson Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics and Estimation: Problems and Solutions
|
Strougo, A(1), Elassaiss-Schaap, J(2), de Greef, HJMM(2), Drenth, H(1) Mechanism-based model of the effect of co-administration of exogenous testosterone and progestogens on the hypothalamic-pituitary-gonodal axis in men
|
Teun Post(1), Tomoo Funaki(2), Hiromi Maune(2), Henk-Jan Drenth(1) Circadian rhythm in pharmacodynamics and its influence on the identification of treatment effects
|
Stefano Zamuner, Roberto Gomeni Optimal Design to Estimate the Time Varying Receptor Occupancy Relationship in a PET Experiment
|
Dartois C, Looby M, He H, Steimer J-L, and Pillai G. Impact of handling missing PK data on PD estimation – explicit modeling of BLQ data in WinBUGS® reduced bias in the PD predictions - a preclinical example.
|
Robert J. Bauer Advanced Population Analysis Features in the S-ADAPT/MCPEM Program
|
Tim Sheiner Planning To Communicate
|
Justin J Wilkins (1,2), Radojka M Savic (2), Mats O Karlsson (2), Grant Langdon (1), Helen McIlleron (1), Goonaseelan (Colin) Pillai (3), Peter J Smith (1), Ulrika SH Simonsson (2,4) A flexible approach to modeling variable absorption in the context of repeated dosing: illustrated with rifampicin
|
Benoit You (1,2) , Paul Perrin (1,2), Philippe Paparel (1,2), Gilles Freyer (1,2), Olivier Colomban (1) Brigitte Tranchand (1,3), Pascal Girard (1) Kinetic models of PSA decrease after surgery in prostate tumor diseases as a help for clinician interpretation
|
Francesca Del Bene, Massimiliano Germani, Maurizio Rocchetti, Alex De Giorgio-Miller, Nick Pullen, Peter Bungay, Chris Kohl & Piet van der Graaf A population PK-PD method for categorical data analysis of progesterone antagonist activity in the rabbit McPhail’s model
|
C. Dansirikul, M.O. Karlsson Insulin secretion and hepatic extraction during euglycemic clamp study: modelling of insulin and C-peptide data
|
Joakim Nyberg, Mats O Karlsson, Andrew Hooker Sequential versus simultaneous optimal experimental design on dose and sample times
|
F. Mentré (1), S. Duffull (2), I. Gueorguieva (3), A. Hooker (4), S. Leonov (5), K. Ogungbenro (6), S. Retout (1) Software for optimal design in population pharmacokinetics and pharmacodynamics: a comparison
|
Kim Stuyckens, Stefaan Rossenu, Peter King, Janine Arts, Juan Jose Perez-Ruixo. Modeling Drug Effects and Resistance Development on Tumor Growth Dynamics
|
Kristin E. Karlsson(1), Justin Wilkins(1,3), Mats O. Karlsson(1) and E. Niclas Jonsson(1,2) Modelling of disease progression in acute stroke by simultaneously using the NIH stroke scale, the Scandinavian stroke scale and the Barthel index
|
M. Lavielle (1,2), H. Mesa (3,2), F. Mentré (4,5) The SAEM algorithm and its implementation in MONOLIX 2.1
|
Philippe Jacqmin (1), Lynn McFadyen (2) and Janet R. Wade (1) Basic PK/PD principles of proliferative and circular systems
|
E.H. Cox (1)(3), N.H. Prins (1), G. D’Souza (2) & L. McFadyen (2) Integrated Modeling & Simulation of Clinical Response and Drop-out of D2 receptor agonists in Patients with Early Parkinson’s Disease.
|
Claudio Cobelli Models of Glucose Metabolism and Control in Diabetes
|